Eisai is advancing clinical development of two LATl inhibitors for biliary tract cancer, multiple sclerosis, and other diseases, as well as drug discovery research for the following compounds:

Biliary tract cancer is a disease that causes about 20,000 new diagnoses per year in Japan and Europe, about 14,000 people per year in the United States, and about 44,000 people in China each year. Because subjective symptoms are scarce in the early stages, many patients reach the advanced stage...

Multiple sclerosis is a chronic inflammatory demyelinating neurological disease most commonly found in young adults and is included in the Ministry of Health, Labour and Welfare's designated intractable disease. The average age at diagnosis is relatively young at 32 years old, and more than 60,000 new people are diagnosed worldwide every year...

Eisai is currently focusing on the development of second- line (monotherapy) and first-line therapy (in combination with IC for biliary tract cancer) of Nanbullat, as well as second-line progressive multiple sclerosis without recurrence of JPH034. In addition to this, the KRAS mutation ...